Improved survival in tumor-bearing SCID mice treated with interferon-γ-inducible protein 10 (IP-10/CXCL10)
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Tumor growth requires angiogenesis, which in turn requires an imbalance in the presence of angiogenic and angiostatic factors. We have shown that the CXC chemokine family, consisting of members that are either angiogenic or angiostatic, is a major determinant of tumor-derived angiogenesis in non-small-cell lung cancer (NSCLC). Intratumor injection of interferon-inducible protein 10 (IP-10, or CXCL10), an angiostatic CXC chemokine, led to reduced tumor growth in a SCID mouse model of NSCLC. In this study, we hypothesized that treatment with CXCL10 would, by restoring the angiostatic balance, improve long-term survival in NSCLC-bearing SCID mice. To test this hypothesis, A549 NSCLC cells were injected in the subcutis of the flank, followed by intratumor injections with CXCL10 continuously (group I), or for ten weeks (group II), or a control group (human serum albumin). Median survival was 169, 130, and 86 days respectively (P<0.0001). We extended these studies to examine the mechanism of prolonged survival in CXCL10-treated mice. CXCL10 treatment inhibited lung metastases, but was dependent upon continued treatment, and was associated with an increased rate of apoptosis in the primary tumor, with no direct effect on the proliferation of the NSCLC cells. Furthermore, the inhibition of lung metastases was due to the angiostatic effect of CXCL10 on the primary tumor, since the rate of apoptosis within lung metastases was unaffected. These data suggest that anti-angiogenic therapy of human lung cancer should be continued indefinitely to realize persistent benefit, and confirms the anti-metastatic capacity of localized angiostatic therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Virus‐mediated expression of CXCL10, CXCL11, or recombinant CXCL10 injection in tumors was able to increase the infiltration of anticancer T cells in mice [364, 374, 375].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [375]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
O'Reilly, M. (1994) · Cell · doi:10.1016/0092-8674(94)90200-3 · Cited by 3,345
Fidler, I. J. (1990) · PubMed · Cited by 1,278
Angiostatin induces and sustains dormancy of human primary tumors in mice
O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,184
Good, D. J., Polverini, P. J., Rastinejad, F., Le Beau, M. M., Lemons, R. S., Frazier, W. A., & Bouck, N. P. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.17.6624 · Cited by 1,054
TUMOR DORMANCY IN VIVO BY PREVENTION OF NEOVASCULARIZATION
Gimbrone, M. A., Leapman, S. B., Cotran, R. S., & Folkman, J. (1972) · The Journal of Experimental Medicine · doi:10.1084/jem.136.2.261 · Cited by 903
Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
Sgadari, C., Angiolillo, A., & Tosato, G. (1996) · Blood · doi:10.1182/blood.v87.9.3877.bloodjournal8793877 · Cited by 469
Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
Rastinejad, F., Polverini, P. J., & Bouck, N. P. (1989) · Cell · doi:10.1016/0092-8674(89)90238-9 · Cited by 463
Relation of vascular proliferation to tumor growth.
Folkman, J., & Cotran, R. S. (1976) · PubMed · Cited by 411
Romagnani, P., Annunziato, F., Lasagni, L., Lazzeri, E., Beltrame, C., Francalanci, M., Uguccioni, M., Galli, G., Cosmi, L., Maurenzig, L., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci9775 · Cited by 379
Van Meir, E. G., Polverini, P. J., Chazin, V. R., Su Huang, H.-J., de Tribolet, N., & Cavenee, W. K. (1994) · Nature Genetics · doi:10.1038/ng1094-171 · Cited by 307
Research works printed but not linked: 6
- American Cancer Society (2001) 2000 Cancer Facts and Fig- ures: Selected Cancers, Vol. 2000. American Cancer Society, Atlanta
- Boehm T, Folkman J, Browder T, O'Reilly MS (1997) Anti- angiogenic therapy of experimental cancer does not induce acquired drug resistance [see comments]. Nature 390: 404
- Carney DN (1988) Cancers of the lungs. In: Fishman AP (ed) Pulmonary diseases and disorders. McGraw-Hill, New York, p 1885
- Folkman J (1993) Tumor angiogenesis. In: Holland JF, Frei E, Bast RC, Kufe DW, Morton DL, Weischelbaum RR (eds) Cancer Medicine, Vol. 1. Lea and Febiger, Philadelphia, p 153
- Holmgren L, O'Reilly MS, Folkman J (1995) Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression [see comments]. Nat Med 1: 149
- Sharma S, Stolina M, Luo J, Strieter RM, Burdick M, Zhu LX, Batra RK, Dubinett SM (2000) Secondary lymphoid tissue chemokine mediates T cell-dependent antitumor responses in vivo [In Process Citation]. J Immunol 164: 4558
Cited by
CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - a target for novel cancer therapy
Tokunaga, R., Zhang, W., Naseem, M., Puccini, A., Berger, M. D., Soni, S., McSkane, M., Baba, H., & Lenz, H.-J. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.007 · Cited by 1,627
Key chemokines direct migration of immune cells in solid tumors
Kohli, K., Pillarisetty, V. G., & Kim, T. S. (2022) · Cancer Gene Therapy · doi:10.1038/s41417-021-00303-x · Cited by 583
Mikucki, M. E., Fisher, D. T., Matsuzaki, J., Skitzki, J. J., Gaulin, N. B., Muhitch, J. B., Ku, A. W., Frelinger, J. G., Odunsi, K., Gajewski, T. F., et al. (2015) · Nature Communications · doi:10.1038/ncomms8458 · Cited by 512
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
CXCR3 ligands in disease and therapy
Van Raemdonck, K., Van den Steen, P. E., Liekens, S., Van Damme, J., & Struyf, S. (2015) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2014.11.009 · Cited by 310
CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond
Karin, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00976 · Cited by 278
Chemokines beyond chemo-attraction: CXCL10 and its significant role in cancer and autoimmunity
Karin, N., & Razon, H. (2018) · Cytokine · doi:10.1016/j.cyto.2018.02.012 · Cited by 222
Analysis of the role of chemokines in angiogenesis
Bernardini, G., Ribatti, D., Spinetti, G., Morbidelli, L., Ziche, M., Santoni, A., Capogrossi, M. C., & Napolitano, M. (2003) · Journal of Immunological Methods · doi:10.1016/s0022-1759(02)00420-9 · Cited by 172
Reschke, R., Yu, J., Flood, B. A., Higgs, E. F., Hatogai, K., & Gajewski, T. F. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003521 · Cited by 169
CXCR3, a double-edged sword in tumor progression and angiogenesis
Billottet, C., Quemener, C., & Bikfalvi, A. (2013) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2013.08.002 · Cited by 166
Harnessing the chemokine system to home CAR-T cells into solid tumors
Foeng, J., Comerford, I., & McColl, S. R. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100543 · Cited by 165
Chemokines and cancer: new immune checkpoints for cancer therapy
Karin, N. (2018) · Current Opinion in Immunology · doi:10.1016/j.coi.2018.03.004 · Cited by 158
White, E. S., Flaherty, K. R., Carskadon, S. L., Brant, A., Iannettoni, M. D., Yee, J., Orringer, M. B., & Arenberg, D. A. (2003) · PubMed · Cited by 155
Self-citationChemokines as mediators of tumor angiogenesis and neovascularization
Keeley, E. C., Mehrad, B., & Strieter, R. M. (2010) · Experimental Cell Research · doi:10.1016/j.yexcr.2010.10.020 · Cited by 146
Self-citationCytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
The CC and CXC chemokines: major regulators of tumor progression and the tumor microenvironment
Bikfalvi, A., & Billottet, C. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00378.2019 · Cited by 123
Struyf, S., Burdick, M. D., Peeters, E., den Broeck, K. V., Dillen, C., Proost, P., Damme, J. V., & Strieter, R. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4682 · Cited by 113
Self-citationCXCR3-binding Chemokines: Novel Multifunctional Therapeutic Targets
Lazzeri, E., & Romagnani, P. (2005) · Current Drug Targets - Immune, Endocrine & Metabolic Disorders · doi:10.2174/1568008053174723 · Cited by 112
Heparanase enhances myeloma progression via CXCL10 downregulation
Barash, U., Zohar, Y., Wildbaum, G., Beider, K., Nagler, A., Karin, N., Ilan, N., & Vlodavsky, I. (2014) · Leukemia · doi:10.1038/leu.2014.121 · Cited by 99
Role of Chemokines in Thyroid Cancer Microenvironment: Is CXCL8 the Main Player?
Rotondi, M., Coperchini, F., Latrofa, F., & Chiovato, L. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00314 · Cited by 95
Role of Chemokines in Non-Small Cell Lung Cancer: Angiogenesis and Inflammation
Rivas-Fuentes, S., Salgado-Aguayo, A. R., Belloso, S. P., Rosete, P. G., Alvarado‐Vásquez, N., & Aquino‐Jarquín, G. (2015) · Journal of Cancer · doi:10.7150/jca.12286 · Cited by 95
Multifaceted role of chemokines in solid tumors: From biology to therapy
Raza, S., Rajak, S., Tewari, A., Gupta, P., Chattopadhyay, N., Sinha, R. A., & Chakravarti, B. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.12.011 · Cited by 85
Feldman, E. D., Weinreich, D. M., Carroll, N. M., Burness, M. L., Feldman, A. L., Turner, E. M., Xu, H. M., & Alexander, H. R. (2005) · Annals of Surgical Oncology · doi:10.1245/aso.2006.03.038 · Cited by 83
Interferons as antiangiogenic agents
Lindner, D. J. (2002) · Current Oncology Reports · doi:10.1007/s11912-002-0065-4 · Cited by 78
Targeted in vivo expression of IFN-γ-inducible protein 10 induces specific antitumor activity
Yang, X., Chu, Y., Wang, Y., Zhang, R., & Xiong, S. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0306212 · Cited by 76
Role of Chemokine (C–X–C Motif) Ligand 10 (CXCL10) in Renal Diseases
Gao, J., Wu, L., Wang, S., & Chen, X. (2020) · Mediators of Inflammation · doi:10.1155/2020/6194864 · Cited by 74
Effect of low frequency magnetic fields on melanoma: tumor inhibition and immune modulation
Nie, Y., Du, L., Mou, Y., Xu, Z., Weng, L., You-Wei, D., Zhu, Y., Hou, Y., & Wang, T. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-582 · Cited by 70
Li, G., Tian, L., Hou, J., Ding, Z., He, Q., Feng, P., Wen, Y., Xiao, F., Yao, B., Zhang, R., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2117 · Cited by 69
CXCL-10: a new candidate for melanoma therapy?
Bagheri, H., Pourhanifeh, M. H., Derakhshan, M., Mahjoubin‐Tehran, M., Ghasemi, F., Mousavi, S., Rafiei, R., Abbaszadeh‐Goudarzi, K., Mirzaei, H. R., & Mirzaei, H. (2020) · Cellular Oncology · doi:10.1007/s13402-020-00501-z · Cited by 65
Inflammatory cytokines are associated with response and prognosis in patients with esophageal cancer
Blank, S., Nienhüser, H., Dreikhausen, L., Sisic, L., Heger, U., Ott, K., & Schmidt, T. (2017) · Oncotarget · doi:10.18632/oncotarget.17671 · Cited by 61
Reschke, R., Enk, A. H., & Hassel, J. C. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25126532 · Cited by 59
Hart, M., Nickl, L., Walch-Rueckheim, B., Krammes, L., Rheinheimer, S., Diener, C., Taenzer, T., Kehl, T., Sester, M., Lenhof, H.-P., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001617 · Cited by 50
Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors
Bronger, H., Magdolen, V., Goettig, P., & Dreyer, T. F. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09807-3 · Cited by 51
Karin, N. (2021) · Cancers · doi:10.3390/cancers13246317 · Cited by 45
Interleukin-17 and type 17 helper T cells in cancer management and research
Housseau, F., Geis, A. L., Orberg, E. T., & Llosa, N. J. (2014) · ImmunoTargets and Therapy · doi:10.2147/itt.s56529 · Cited by 42
The Emerging Role of CXC Chemokines And Their Receptors in Cancer
Vinader, V. M., & Afarinkia, K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.48 · Cited by 42
Plasma Proteomic Analysis in Non-Small Cell Lung Cancer Patients Treated with PD-1/PD-L1 Blockade
Eltahir, M., Isaksson, J., Mattsson, J. S. M., Kärre, K., Botling, J., Lord, M., Mangsbo, S. M., & Micke, P. (2021) · Cancers · doi:10.3390/cancers13133116 · Cited by 39
Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures
Wang, T., Li, T., Li, B., Zhao, J., Li, Z., Sun, M., Li, Y., Zhao, Y., Zhao, S., He, W., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.805184 · Cited by 39
Diversity of the Angiogenic Phenotype in Non–Small Cell Lung Cancer
McClelland, M., Carskadon, S. L., Zhao, L., White, E. S., Beer, D. G., Orringer, M. B., Pickens, A., Chang, A. C., & Arenberg, D. A. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0311oc · Cited by 38
Self-citationYang, L., Chen, P., Luo, S., Li, J., Liu, K., Huo-zhen, H., & Wei, Y. (2009) · Biotechnology and Applied Biochemistry · doi:10.1042/ba20090012 · Cited by 37
Nie, S., Song, Y., Hu, K., Zu, W., Zhang, F., Chen, L., Ma, Q., Zhou, Z., & Jiao, S. (2024) · OncoImmunology · doi:10.1080/2162402x.2024.2358590 · Cited by 30
Murooka, T. T., Ward, S. E., & Fish, E. N. (2005) · Springer eBooks · doi:10.1007/0-387-24361-5_2 · Cited by 27
Development of DPP-4-resistant CXCL9-Fc and CXCL10-Fc chemokines for effective cancer immunotherapy
Lugassy, J., Abdala-Saleh, N., Jarrous, G., Turky, A., Saidemberg, D., Ridner-Bahar, G., Berger, N., Bar-On, D., Taura, T., Wilson, D. S., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2501791122 · Cited by 25
Association between preeclampsia and the CXC chemokine family (Review)
Liu, X., Dai, L., & Zhou, R. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2337 · Cited by 25
Aronica, S. M., Fanti, P., Kaminskaya, K., Gibbs, K., Raiber, L., Nazareth, M. R., Bucelli, R. C., Mineo, M., Grzybek, K., Kumin, M., et al. (2004) · Breast Cancer Research and Treatment · doi:10.1023/b:brea.0000019961.59306.f6 · Cited by 24
Mohit, E., Bolhassani, A., Zahedifard, F., Seyed, N., Eslamifar, A., Taghikhani, M., Samimi‐Rad, K., & Rafati, S. (2012) · Molecular Immunology · doi:10.1016/j.molimm.2012.07.011 · Cited by 23
Salivary cytokine panel indicative of non-small cell lung cancer
Koizumi, T., Shetty, V., & Yamaguchi, M. (2018) · Journal of International Medical Research · doi:10.1177/0300060518775563 · Cited by 22
Ma, Y., Liu, Y., Zhi, Y., Wang, H., Yang, M., Niu, J., Zhao, L., & Wang, P. (2022) · Cancer Nanotechnology · doi:10.1186/s12645-022-00116-z · Cited by 21
Markman, M. M., Belinson, J. L., Webster, K. D., Zanotti, K. M., Morrison, B., Jacobs, B., Borden, E. C., & Lindner, D. J. (2004) · Oncology · doi:10.1159/000079480 · Cited by 21
Mitsuhashi, A., Kondoh, K., Horikawa, K., Koyama, K., Nguyen, N. T., Afroj, T., Yoneda, H., Otsuka, K., Ogino, H., Nokihara, H., et al. (2021) · Cancer Science · doi:10.1111/cas.15161 · Cited by 20
Dholakia, J., Scalise, C. B., Katre, A. A., Goldsberry, W. N., Meza‐Perez, S., Randall, T. D., Norian, L. A., Novak, L., & Arend, R. C. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.09.026 · Cited by 20
Fanti, P., Nazareth, M. R., Bucelli, R. C., Mineo, M., Gibbs, K., Kumin, M., Grzybek, K., Raiber, L., Poppenberg, K., Janis, K. L., et al. (2003) · Endocrine · doi:10.1385/endo:22:2:161 · Cited by 19
Zhu, M., Yang, Z., Yu, H., Zhu, Q., Xu, Y. Y., Li, Y., Li, C., Zhao, W. M., Liang, Z., & Chen, L. (2020) · International Journal of Radiation Biology · doi:10.1080/09553002.2020.1748737 · Cited by 18
Contribution of CXCR3-mediated signaling in the metastatic cascade of solid malignancies
Cannon, A. C., Thompson, C. M., Bhatia, R., Kandy, R. R. K., Solheim, J. C., Batra, S. K., & Kumar, S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188628 · Cited by 17
Coperchini, F., Greco, A., Croce, L., Pignatti, P., Muzza, M., Petrosino, E., Teliti, M., Magri, F., & Rotondi, M. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115974 · Cited by 16
Sahni, S., Wang, B., Wu, D., Dhruba, S. R., Nagy, M. R., Patkar, S., Ferreira, I., Day, C., Wang, K., & Ruppin, E. (2024) · Nature Communications · doi:10.1038/s41467-024-52555-4 · Cited by 15
Aquino, A., & Franzese, O. (2025) · Cancers · doi:10.3390/cancers17091547 · Cited by 13
Wu, X., Lai, X., Tu, H., Zou, H., & Cao, J. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.03.033 · Cited by 13
A novel fusion protein of IP10-scFv retains antibody specificity and chemokine function
Guo, J., Chen, L., Ai, H., Jing, J.-N., Zhou, J., Zhang, C., & Shangyou, Y. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.05.193 · Cited by 13
Liu, Y., & Wang, X. (2021) · Clinical & Translational Oncology · doi:10.1007/s12094-021-02602-z · Cited by 12
Synergistic antitumor effect of CXCL10 with hyperthermia
Chen, P., Yang, L., Yang, H., Wang, Y., Li, G., Wu, Y., Fang, F., Liu, K., Li, J., Zhao, X., et al. (2007) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-007-0337-3 · Cited by 12
Dormancy in the Tumor Microenvironment
Omokehinde, T., & Johnson, R. W. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-73119-9_2 · Cited by 11
Badirzadeh, A., Montakhab‐Yeganeh, H., & Miandoabi, T. (2020) · Journal of Parasitic Diseases · doi:10.1007/s12639-020-01279-5 · Cited by 11
Bellone, G., Novarino, A., Chiappino, I., Gramigni, C., Carbone, A., Addeo, A., Tonel, E., Bertetto, O., & Emanuelli, G. (2005) · PubMed · Cited by 11
Wang, H. R., Zhang, Y., Mo, Y., Zhang, Z., Chen, R., Lu, X. B., & Huang, W. (2024) · Communications Biology · doi:10.1038/s42003-024-06566-y · Cited by 7
Lin, X., Li, H., Li, X., Yang, X., Shi, W., Ding, Z., Zhong, D., Li, Y., Yang, W., Yu, X., et al. (2021) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2021.3140 · Cited by 7
CXCL9, CXCL10, CXCL11/CXCR3 Axis and Immune Activation
Mir, M. A., Javeed, T., & Ishfaq, I. (2023) · Springer eBooks · doi:10.1007/978-981-99-4657-0_10 · Cited by 4
Wang, X., Xing, Y., Zhou, X., Wang, C., Han, S., & Zhao, S. (2024) · Cancer Reports · doi:10.1002/cnr2.70030 · Cited by 4
IP-10 and fractalkine induce cytotoxic phenotype of murine NK cells
Liu, F., Qin, J., Zhang, H., Li, N., Shan, M., Lan, L., & Wang, Y. (2016) · 中国科学通报:英文版 · doi:10.1007/s11434-015-0961-2 · Cited by 2
DACH1 inhibits the proliferation and migration of papillary thyroid carcinoma
Liang, S., Xu, Q., Liu, B., Hu, R., Lai, J., Wang, W. J., Yu, X., Gou, J., Wang, L., Chen, Y., et al. (2022) · Cell Biology International · doi:10.1002/cbin.11961 · Cited by 2
Weng, C., Schochet, C., Panneton, V., Assouvie, A., Eghbali, S. Z., Monette, S., Liu, C., Marouf, Y., Mangarin, L. M. B., Morgado-Palacin, L., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117443 · Cited by 1
Dockry, É. (2016) · Arrow@dit (Dublin Institute of Technology) · Cited by 1
Impact of Targeting the Autophagy Related Gene Beclin 1 on the Immune Landscape of Melanoma
Arakelian, T. (2018) · theses.fr (ABES) · doi:10.70675/cd5f1ed6z9100z4dd3zb7fazb0537054f400 · Cited by 1
The Role of the CXCR3 Signaling Axes in Pancreatic Ductal Adenocarcinoma
Cannon, A. C. (2020) · DigitalCommons@UNMC
Ma, Y., Liu, Y., Zhi, Y., Wang, H., Yang, M., Niu, J., Zhao, L., & Wang, P. (2022) · Figshare · doi:10.6084/m9.figshare.19654651
Immecke, S. N., & Justus Liebig University Giessen (2009) · University writing server of the Justus Liebig University Giessen (Justus-Liebig-Universität Gießen) · doi:10.22029/jlupub-10135
Genetic adjuvants for immunotherapy
Mohapatra, S. S., & Kumar, M. (2009) · Digital Commons - University of South Florida (University of South Florida)
佐藤, 友. (2021) · Institutional Repositories DataBase (IRDB)
Wang, T., Li, T., Li, B., Zhao, J., Li, Z., Sun, M., Li, Y., Zhao, Y., Zhao, S., He, W., et al. (2022) · doi:10.3389/fimmu.2022.805184.s001
Metadata
- Authors
- Arenberg, D., White, E., Burdick, M., Strom, S., & Strieter, R.
- Affiliations
- University of Michigan (US)
- University of California, Los Angeles (US)
- Corresponding author
- Arenberg, Douglas
- Venue
- Cancer Immunology Immunotherapy
- Published
- 2001-12-01
- Volume
- 50
- Issue
- 10
- Pages
- 533-538
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- PMC
- PMC11032922
- OpenAlex
- W2027099531
- Cited by
- 73
- References
- 12
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 5 · 2023: 3 · 2022: 6 · 2021: 10 · 2020: 8 · 2019: 2 · 2018: 5 · 2017: 2 · 2016: 1 · 2015: 3 · 2014: 3 · 2013: 2 · 2012: 2
- FWCI
- 1.18
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Cancer Immunology Immunotherapy (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Deep Blue (University of Michigan) (submittedVersion)
- Funders
- National Institutes of Health (5k08ca072543-05, CA72543, P50HL67665)
- National Heart, Lung, and Blood Institute (HL66027, P50-HL-67665, P50HL067665, R01HL066027)
- National Cancer Institute (CA-87879, R01CA087879, CA72543)
- Topics
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Keywords
- CXCL10, non-small cell lung cancer, tumor angiogenesis, anti-angiogenic therapy, lung metastasis, tumor cell apoptosis, intratumoral injection, long-term survival, A549 cells, SCID mice
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Female, Humans, Interferon-gamma, Lung Neoplasms, Neovascularization, Pathologic, Tumor Cells, Cultured, Survival Analysis, Mice, SCID, Chemokines, CXC, Mice, Chemokine CXCL10
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.